

Haematologica
HAEMATOL/2020/255950
Version 3

Molecular Attributes Underlying Central Nervous System and Systemic
Relapse in Diffuse Large B-cell Lymphoma

Keren Isaev, Daisuke Ennishi, Laura Hilton, Brian Skinnider, Karen L. Mungall, Andrew J. Mungall, Mehran Bakhtiari, Rosemarie Tremblay-LeMay, Anjali Silva, Susana Ben-Neriah, Merrill Boyle, Diego Villa, Marco A. Marra, Christian Steidl, Randy D. Gascoyne, Ryan Morin, Kerry J. Savage, David W. Scott, and Robert Kridel

Disclosures: Villa: Roche, Abbvie, Celgene, Seattle Genetics, Lundbeck, AstraZeneca, Nanostring, Janssen, Gilead: Consultancy, Honoraria. AstraZeneca: Research Funding (institution). Savage: Bristol-Myers Squibb, Merck, Seattle Genetics, Astra Zeneca, Gilead, Abbvie. Consulting: Servier. Steering committee: Beigene. Scott: Roche/Genentech: Research Funding; Celgene: Consultancy; Janssen: Consultancy, Research Funding; NanoString: Patents & Royalties: Named inventor on a patent licensed to NanoString [Institution], Research Funding. Kridel: Gilead Sciences: Research Funding; Roche: Travel Support.

Contributions: R.K. and D.W.S designed the study, collected data, analyzed data and wrote the manuscript. K.I. analyzed data and wrote the manuscript. D.E., B.S., M.B., R.TL., B.M., S.BN. and M.B. reviewed samples, extracted and inventoried samples and/or provided data. L.H. and R.M. provided outcome analyses based on SLAMF1 expression in external datasets. K.M., A.J.M. and M.A.M. provided critical support for exome sequencing and analysis. D.V., C.S., R.D.G and K.J.S. provided samples and clinical data. A.S. reviewed and corrected bioinformatic scripts related to this manuscript. All authors approved the final version of the manuscript.